Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05963074 2026-04-13

TAILOR

Phase 2 Recruiting

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06136559 2026-04-13

BELLWAVE-011

Phase 3 Recruiting

1,200 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06299540 2026-04-13

QOLIBRI

Recruiting

180 enrolled

Phase 1 Enrolling by invitation

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06788509 2026-04-13

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

120 enrolled

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT05254743 2026-04-01

BRUIN-CLL-314

Phase 3 Recruiting

662 enrolled

Phase 3 Active not recruiting

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT02477696 2026-03-27

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

533 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03331198 2026-03-04

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase 1/2 Recruiting

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 2 Completed

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04876092 2025-08-21

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

45 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03190330 2025-05-25

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Phase 4 Completed

75 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03400176 2025-05-16

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Phase 1 Terminated

39 enrolled 30 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04494503 2025-04-16

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Phase 1/2 Recruiting

123 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03734016 2025-03-30

ALPINE

652 enrolled 27 charts 2 FDA

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03088878 2025-02-12

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

95 enrolled 25 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02743546 2025-02-03

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Phase 1 Withdrawn

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03476655 2025-02-03

Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India

Completed

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02910583 2024-12-20

Captivate

Phase 2 Completed

323 enrolled 33 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01724346 2024-09-19

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

269 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02733042 2023-11-18

FUSION NHL 001

106 enrolled 48 charts

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02352558 2023-11-14

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

15 enrolled

Lymphoma, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04016805 2023-07-24

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Phase 2 Terminated

41 enrolled 4 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02013128 2022-10-24

Ublituximab + Ibrutinib in Select B-cell Malignancies

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03425591 2022-10-06

FIRE

Completed

508 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02301156 2022-05-20

GENUINE

126 enrolled 18 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03720561 2022-01-03

EVIdeNCE

Completed

312 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02406742 2021-09-20

ENHANCE

47 enrolled 15 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01644253 2021-05-20

Phase 1b Safety and Efficacy Study of TRU-016

Phase 1 Terminated

87 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Peripheral

NCT02759016 2020-09-29

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

7 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02264574 2020-09-21

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

229 enrolled 29 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01109069 2020-05-27

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Phase 2 Completed

199 enrolled 14 charts

Burkitt Lymphoma, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT01611090 2020-03-03

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

578 enrolled 21 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01578707 2019-12-18

RESONATE™

391 enrolled 14 charts

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03301207 2019-12-05

A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

25 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02006485 2019-11-05

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

160 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02973399 2019-02-22

Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL

Phase 1 Terminated

5 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02914327 2018-07-30

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Phase 1 Withdrawn

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01973387 2018-07-24

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

160 enrolled 12 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01722487 2017-11-30

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

269 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02381080 2017-06-26

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

26 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02437019 2017-03-20

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Approved for marketing

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01217749 2015-06-25

PCYC-1109-CA

71 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01292135 2014-07-24

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

33 enrolled 13 charts

Leukemia, Lymphoid, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01105247 2014-03-31

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

133 enrolled 10 charts